



Neuland Q4FY25 Total income at Rs.335.8 crore; EBITDA at Rs.58.2 crore

Hyderabad, India, May 15, 2025 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the fourth quarter & full year ended March 31st, 2025.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“We saw marginal decrease in topline in FY25 as compared to FY24. which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for FY25. During the course of the year we have committed to making investments which will significantly drive our growth in the medium and long term. Neuland continues to be recognized for its capabilities and quality track record, and we have good visibility on short and long term growth”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *“The CMS revenues of Rs. 637 crores were largely driven by molecules in the commercial segment. Even though the revenues have declined this year, we continue to see good traction in business from a wider range of customers Our peptide investment plan is on track. We continue to garner more projects in this space which further validates our excitement about the opportunities that the segment holds. At an overall level, we have molecules in our portfolio which are currently at the take off stage, therefore we expect our growth trajectory to resume in FY26.”*

Financial Summary

Particulars	Rs. crore							
	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	FY25	FY24	YoY (%)
Total Income	335.8	390.4	-14.0%	401.9	-16.4%	1,497.3	1,571.1	-4.7%
EBITDA	58.2	112.2	-48.1%	90.3	-35.5%	342.8	474.5	-27.7%
EBITDA margin (%)	17.3%	28.7%	-1140 bps	22.5%	-520 bps	22.9%	30.2%	-730 bps
Exceptional Item*	-	-	-	55.8	-	76.4	-	-
PAT*	27.7	67.6	-59.0%	101.4	-72.7%	259.4	299.6	-13.4%
PAT margin (%)	8.3%	17.3%	-900 bps	25.2%	-1690 bps	17.3%	19.1%	-180 bps
EPS (Basic) Rs.	21.6	52.7	-59.0%	79.0	-72.7%	202.2	233.5	-13.4%

*Q3FY25 and FY25 Includes exceptional item of sale of investment property of Rs. 55.8 crores and Rs. 76.4 crores respectively.

Q4 FY25 Earnings Call

The company will conduct a one-hour Earnings call at **17:00 hrs. IST on Thursday, May 15, 2025** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 980 Regulatory filings across the US (72 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com